Relapsed and refractory multiple myeloma
Conditions
Interventions
treatment group:Murine BCMA-CART Cell Immunotherapy
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with relapsed or refractory multiple myeloma with CART treatment target (BCMA or CD269); 2. Patients must have evaluable disease certificates, including minimal residual disease; 3, Aged 18 to 70 years, including the boundary value, have the ability to know, can sign informed and voluntary consent; 4. The estimated survival period is more than 3 months; 5, ECOG score 0-2 points; 6. Women of childbearing age were negative for the blood pregnancy test before the start of the trial and agreed to take effective contraceptive measures during the trial period until the last follow-up.
Exclusion criteria
Exclusion criteria: 1. Intracranial hypertension or unconsciousness; 2. Symptomatic heart failure or severe arrhythmia; 3. Respiratory failure; 4. With other types of malignant tumors; 5. Diffuse vascular internal coagulation; 6. Serum creatinine and / or urea nitrogen >= 1.5 times the normal value; 7. Sepsis or other uncontrollable infections; 8. Uncontrollable diabetes; 9. Severe mental disorders; 10. Head MRI examination has obvious lesions in the skull; 11. Examination of leukemia cells by cerebrospinal fluid > 20/ul; 12. The proportion of blood tumor cells is >30%; 13. Organ transplant recipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;complete remission rate;Progression-free survival (PFS); | — |
Countries
China
Contacts
Public ContactChunrong Tong, Xiaoyan Ke
Beijing Boren Hospital
Outcome results
None listed